Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study-Reference-Cited by-同舟云学术

Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study

Published:2023-01 Issue: Volume:38 Page:117-125
ISSN:2214-031X
Container-title:Journal of Orthopaedic Translation
language:en
Short-container-title:Journal of Orthopaedic Translation

Author:

Gu Jiemei,Zhang Hao,Xue Qingyun,Wang Li,Cheng Zhifeng,Zhang Yawei,Li Qifu,Yuan Lingqing,Li Yukun,Dong Jin,Huo Yanan,Tang Xin,Hu Ling,Wang Xinjia,Hua Fei,Shen Lin,Cheng Jinluo,Zhou Huimin,Xu Youjia,Yang Tao,Wang Chuansuo,Xu Jin,Shen Jie,Zhang Ying,Zhang Xiaomei,Hong Dun,Guan Xiaoling^ORCID,Xiao Xinhua,Wang Guang,Liu Yonghua,Fu Liujun,Chen Jianting,Cheng Xigao,Ding Yue,Liu Lijun,Yao Qi,Zhang Xinchao,Li Lixin,Zhang Panjun,Deng Chunying,Jiang Chengyan,You Li,Wang Kai,Zhang Shimin,Xiao Jianzhong,Liu Wei,Du Xiaohong,Shang Xianwen,Pan Tianrong,Lei Chen,Guo Shuren,Zhang Zhenlin

Publisher

Elsevier BV

Subject

Orthopedics and Sports Medicine

Reference17 articles.

1. Osteoporosis: now and the future;Rachner;Lancet,2011

2. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases;Hofbauer;JAMA,2004

3. Denosumab in postmenopausal women with low bone mineral density;McClung;N Engl J Med,2006

4. AMERICAN association of clinical endocrinologists/AMERICAN college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal OSTEOPOROSIS-2020 update;Camacho;Endocr Pract,2020

5. Amgen. Amgen PROLIA (denosumab) prescribing information. Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125320s202lbl.pdf.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis;Osteoporosis International;2024-07-23

2. Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis;Expert Opinion on Biological Therapy;2024-05-16

3. Piperlongumine, a Piper longum-derived amide alkaloid, protects mice from ovariectomy-induced osteoporosis by inhibiting osteoclastogenesis via suppression of p38 and JNK signaling;Food & Function;2024

4. 2023 January issue Journal of Orthopaedic Translation;Journal of Orthopaedic Translation;2023-01

5. Side effects of drugs for metabolic bone disease;Side Effects of Drugs Annual;2023